TMPRSS2:ETS gene fusions in prostate cancer


Julia L Williams, Maisa Yoshimoto, Alexander H Boag, Jeremy A Squire, Paul C Park*

Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
* Kingston General Hospital, 76 Stuart Street, Douglas 4, Room 8-431, Kingston, Ontario, Canada K7L 2V7
Phone: 613-549-6666, Ext 4405, Fax: 613-548-1356


December 2010



Table of Contents
I. Background
I.i. Prostate cancer oncogenomics
II. Discovery of TMPRSS2:ETS fusion genes in prostate cancer
III. Frequency of TMPRSS2:ETS gene fusions in prostate cancer
IV. TMPRSS2:ETS gene fusions: genes and protein structure
IV.i. TMPRSS2 and the androgen receptor
IV.ii. ETS transcription factors
V. Fusion variants
VI. Detection and classification
VI.ii. Other methods of detection
VII. Fusion gene formation and chromosomal instability
VIII. Heterogeneity of multifocal disease
IX. Prognostic significance
X. Clinical utility
XI. Role of ETS in prostate tumourigenesis: Driver?
XII. Concluding remarks


I. Background

Prostate cancer (CaP) is the most commonly diagnosed male malignancy and a leading cause of cancer deaths in developed countries. With one in six men diagnosed, CaP remains a serious global public health issue (Jemal et al., 2008). CaP is a clinically heterogeneous disease, with manifestations ranging from a rapid and often fatal progression, to the typical, indolent disease which remains relatively insignificant to a patient's health. Clinicopathological criteria, including Gleason grading, are not sufficient to differentiate men whose tumours require immediate and aggressive therapy from those that would suffice with vigilant clinical observation, thereby causing the latter group enormous amounts of unnecessary treatment (Yao and Lu-Yao, 2002). In this regard, the emerging data on the genetics of CaP hold great promise not only in stratifying this heterogeneous group of patients, but also in providing the groundwork for future development of targeted therapy.

I.i. Prostate cancer oncogenomics

Advances in cytogenetics and genomics facilitated the characterization of common genomic alterations in CaP, which are predominantly characterized by deletions (10q, PTEN; 13q, RB1; 8p, NKX3.1 (a prostate-specific tumour suppressor); 5q; 2q; 17p; and less commonly 6q; 7p; 16q; 18q) with only a small number of recurrent gains (8q, MYC; and chromosome 7). More complex patterns as well as an accumulation in the number of genomic gains and amplifications (Xq11.2-q12, androgen receptor (AR)) emerge as the disease advances. Genomic rearrangements leading to the formation of TMPRSS2:ETS gene fusions and deletion of the PTEN tumour suppressor are the two most frequent alterations observed in CaP (Tomlins et al., 2005; Yoshimoto et al., 2007; Yoshimoto et al., 2008). The TMPRSS2:ERG gene fusion is the principle genomic alteration and a characteristic signature in approximately half of prostatic malignancies.

II. Discovery of TMPRSS2:ETS fusion genes in prostate cancer

The discovery of the TMPRSS2:ERG gene fusion exemplifies the current shift in the strategy in cancer genomics from experimental to bioinformatics approaches. By surveying 132 gene-expression CaP datasets from the Oncomine database (Compendia Bioscience) using the data transformation algorithm cancer outlier profile analysis (COPA), Chinnaiyan and colleagues identified genes with aberrant expression profiles in a subset of samples (Tomlins et al., 2005). COPA allowed the systematic investigation of cancer-related genes known to participate in chromosomal rearrangements in haematological malignancies and sarcomas. Two mutually exclusive Erythroblastosis virus E26 transformation-specific (ETS) transcription factors, ETS variant 1 (ETV1, 7p21.3) and ETS-related gene (ERG, 21q22.2), were identified as high-ranking outliers in several independent gene-expression profiling datasets. Exon-walking quantitative PCR (qPCR) of patient samples found the 3' regions of ERG and ETV1 to be overexpressed but the corresponding 5' regions were absent. 5' RNA ligase-mediated rapid amplification of cDNA ends identified the 5' end of these transcripts as the promoter sequences belonging to the prostate-specific, androgen regulated transmembrane protease, serine II (TMPRSS2, 21q22.3).

III. Frequency of TMPRSS2:ETS gene fusions in prostate cancer

This breakthrough study reported that 79% of radical prostatectomy (RP) samples harboured a fusion of the 5' untranslated region (UTR) of TMPRSS2 with the coding sequences of either ERG or ETV1 (Tomlins et al., 2005). Interestingly, just months prior, Petrovics et al. (2005) reported that ERG was the most commonly overexpressed oncogene in CaP by microarray and qPCR analysis. Subsequent studies showed that the frequency of the TMPRSS2:ERG fusion gene (or ERG rearrangement) is exceptionally variable and inconsistent in the literature, ranging from 27% to 79% in radical prostatectomy (RP) and biopsy samples, generally from prostate-specific antigen (PSA) screened cohorts (Tomlins et al., 2005; Yoshimoto et al., 2008; Mehra et al., 2007b; Watson et al., 2009; Barwick et al., 2010; Magi-Galluzzi et al., 2010).
Some of the discrepancies in frequency relate to differences in the patient cohort (race as well as global geographical location or PSA-screened versus population based) or the type of specimen examined, as well as the technique used to detect the fusion gene. This concept is clearly illustrated when comparing population based cohorts, which have a lower reported frequency of 15-35%, as compared to RP cohorts (Attard et al., 2008a; Demichelis et al., 2007; Fitzgerald et al., 2008). The TMPRSS2:ERG gene fusion is found in approximately half of Caucasian patients, with a lower reported frequency in African-American men and is less common in Asian cohorts (Mosquera et al., 2009; Magi-Galluzzi et al., 2010; Lee K et al., 2010; Miyagi et al., 2010). An excellent example of discrepancies based on patient populations was demonstrated in a study that compared patients from the United Kingdom (UK) and China, wherein 41.3% of the UK patients but only 7.5% of Chinese cohort were found to harbour ERG rearrangements detected by FISH (Mao et al., 2010). The recent, contradicting report that 90% of the Chinese RP specimens harboured ETS rearrangements further emphasize the multifactorial nature of the variability in the frequency of this gene fusion (Sun et al., 2010).

TMPRSS2:ERG gene fusions are reported in 10-21% of high-grade prostatic intraepithelial neoplastic (HGPIN) lesions, but are identified almost exclusively adjacent to fusion-positive cancer (Cerveira et al., 2006; Perner et al., 2007; Carver et al., 2009b; Han et al., 2009; Zhang et al., 2010; Mosquera et al., 2008). Benign prostatic hyperplasia (BPH) and normal epithelium are negative for ERG rearrangements and fusion transcripts, with the exception of the report by Clark and colleagues (Rajput et al., 2007; Wang et al., 2006; Cerveira et al., 2006; Clark et al., 2007; Perner et al., 2007; Dai et al., 2008; Han et al., 2009; Mosquera et al., 2009; Zhang et al., 2010; Sun et al., 2010; Lu et al., 2009). This study found that eight of 17 (47%) normal epithelial samples adjacent to fusion-positive CaP were also positive for TMPRSS2:ERG rearrangements and found a 6% fusion-positive rate in BPH samples (Clark et al., 2007). Hormone refractory and/or metastatic CaP exhibits less variability in the occurrence of TMPRSS2:ERG rearrangements with reported frequencies ranging from 29-59% (Perner et al., 2007; Mehra et al., 2008; Gopalan et al., 2009; Han et al., 2009; Boormans et al., 2010; Saramaki et al., 2008; Attard et al., 2009; Stott et al., 2010). Additionally, minute prostatic adenocarcinoma, a form of CaP that is considered less clinically significant, harbours ETS fusions in approximately half of reported cases, underscoring the necessity of examining all prostatic malignancies for aggressive features such as the fusion gene (Albadine et al., 2009).

Investigators have also evaluated this rearrangement in the peripheral and transitional zones of the prostate. Nearly half of the peripheral tumours (43.3%) derived from RP samples were ERG rearrangement positive, whereas all 30 corresponding transitional tumours displayed a normal ERG locus by FISH (Guo et al., 2009). In contrast, other studies found TMPRSS2:ERG (13.3%) and ERG rearrangements (11.9%) are present in transitional zone tumours, despite being identified at a lower rate compared to peripheral zone lesions (Bismar and Trpkov, 2010; Falzarano et al., 2010). These data illustrate the enormous variability in the frequency of TMPRSS2:ERG fusion positivity with respect to the cohort, disease stage, origin of sample as well as the method of detection.

Interestingly, a comprehensive study of patient samples from 54 tumour types, including sarcomas and haematological malignancies, for ETS gene fusions and ERG rearrangements by FISH found these alterations to be exclusive to CaP samples (Scheble et al., 2010). The same result was obtained when RT-PCR was performed to detect TMPRSS2:ERG and TMPRSS2:ETV1 fusion transcripts in gastric and colorectal carcinomas (Yoo et al., 2007). These findings provide strong evidence that TMPRSS2:ETS gene fusions are specific to CaP.

IV. TMPRSS2:ETS gene fusions: genes and protein structure

IV.i. TMPRSS2 and the androgen receptor

TMPRSS2, a 70 KDa serine protease family member is associated with physiological and pathological processes such as digestion, tissue remodelling, blood coagulation, fertility, inflammatory responses, tumour cell invasion and apoptosis. The normal function of this protein is not yet known but is composed of a type II transmembrane domain, receptor class A low density lipoprotein domain, scavenger receptor cysteine-rich domain, protease domain, and cytoplasmic domain (Paoloni-Giacobino et al., 1997). The 32 KDa serine protease domain undergoes autocleaveage, secretion into the prostate epithelia and interacts with cell surface proteins, the extracellular matrix and proteins of neighbouring cells (Vaarala et al., 2001; Wilson et al., 2005; Afar et al., 2001). The TMPRSS2 (21q22.3) gene is composed of 14 exons, with protein coding sequences only in the latter half. Importantly, TMPRSS2 harbours androgen responsive elements (ARE) in its 5' UTR. Prostate epithelial cells express TMPRSS2 at higher levels relative to other tissues, while TMPRSS2 gene expression is further elevated in CaP relative to BPH and normal prostatic epithelium (Afar et al., 2001). Androgens and the AR are essential to the growth and development of the prostate gland but also play an important role in the initiation and progression of CaP (Balk et al., 2008). It is well established that despite chemical castration the AR functions to drive CaP, likely through a variety of mechanisms such as hypersensitivity to low levels of androgens, activation in absence of, or via unconventional ligands, or amplification of the AR gene locus, resulting in elevated levels of AR protein. All of these mechanisms could potentially allow AR activation in the presence of low androgen concentration (Ai et al., 2009; Kawata et al., 2010; Vis and Schroder, 2009). Consequently, TMPRSS2 in turn plays an important role in CaP progression in spite of hormonal ablation regimens as its promoter region drives the expression of the fused ETS gene.

IV.ii. ETS transcription factors

Twenty-seven human ETS transcription factor family members have been identified, all of which share a conserved DNA binding domain that recognizes unique sequences containing GGA(A/T) (Nye et al., 1992). ERG (21q22.2) is the ETS transcription factor most commonly known to participate in CaP gene fusions. The ERG gene contains 11 exons, with the transcriptional start site in exon 3. The ERG protein can interact with ETS members as well as other transcription factors, such as Jun and Fos, through its protein-protein interacting domain, SAM-PNT (Carrere et al., 1998; Verger et al., 2001; Basuyaux et al., 1997). The conserved ETS DNA binding domain permits binding to purine rich DNA sequences (Reddy et al., 1991; Reddy et al., 1987), and in this manner, exert its effects in numerous cellular processes including membrane remodelling, angiogenesis, differentiation, proliferation, and tumourigenesis (Carver et al., 2009a; Kruse et al., 2009; Oikawa et al., 2003; Randi et al., 2009; Ellett et al., 2009; Birdsey et al., 2008; Mclaughlin et al., 2001; Sato et al., 2001). Emerging evidence suggests that formation of the fusion gene may promote prostatic tumourigenesis, progression, and invasive disease and is associated with CaP-related mortality (Demichelis et al., 2007; Klezovitch et al., 2008; Wang et al., 2008; Hawksworth et al., 2010). Functionally, ERG overexpression in CaP is highly implicated in promoting motility and invasiveness (Perner et al., 2007; Singh et al., 2002; Trojanowska et al., 2000; Tomlins et al., 2008a; Sreekumar et al., 2009; Schulz et al., 2010). In CaP, ERG expression has been associated with elevated levels of histone deactylase 1 (HDAC1) and subsequent down regulation of HDAC1 target genes, upregulation of WNT pathway proteins, and inhibition of apoptotic signalling (Iljin et al., 2006). HDAC1 upregulation is common in CaP, but was found to be uniformly increased in ERG rearranged tumours (Iljin et al., 2006; Bjorkman et al., 2008). Activation of the WNT pathway leads to transcription of numerous genes involved in tumourigenesis, including AR, MYC, JUN, cyclinD1, BMP4 and MMP7 (Terry et al., 2006; Schweizer et al., 2008). Highlighting the importance of WNT pathway activation in fusion-positive CaP is the resultant increase in AR transcription and expression levels. Consequently transcription of the fusion gene is increased, further amplifying ERG expression. Moreover, beta-catenin and the AR interact in an androgen-dependent manner to regulate AR target genes, whereas in androgen-insensitive tumours, both beta-catenin and AR target genes are expressed (Schweizer et al., 2008).

ERG overexpression has recently been shown to activate C-MYC and result in its overexpression. These experiments revealed that C-MYC is activated by ERG and together their co-overexpression results in the suppression of prostate-epithelial differentiation genes and shorter time to biochemical recurrence (Hawksworth et al., 2010; Sun et al., 2008). ERG can also induce ICAM2 expression, resulting in AKT activation via PDK1 and subsequent inhibition of BAD leading to suppression of apoptotic signals (Mclaughlin et al., 2001). In addition, ERG can bind BRCA1, a co-activator of the AR, and together were shown to regulate IGFR expression (Chai et al., 2001; Schayek et al., 2009). IGFR expression eventually leads to activation of AKT upon IGFR ligand-binding. ERG regulates MMPs thus influencing extracellular matrix (ECM) remodelling and the invasive potential of the cell (Ellett et al., 2009; Hawksworth et al., 2010; Singh et al., 2002; Schulz et al., 2010). Recently, Carver and colleagues have identified ETS binding sites in the promoter regions of CXCR4 and ADAMTS1, two genes involved in cellular motility and invasion (Carver et al., 2009a). Furthermore, it was shown that ERG directly upregulates the expression level of CXCR4 and ADAMTS1 (Carver et al., 2009b). Together, these studies provide a compelling evidence for a central, functional role of the fusion gene in the biology of prostatic carcinoma.

V. Fusion variants

The TMPRSS2:ERG fusion gene constitutes the majority (>85%) of ETS rearrangements in CaP, likely owing to their close proximity (2.7 Mb) and identical orientation on chromosome 21. Although, the remainder of this review will predominately focus on the TMPRSS2:ERG rearrangement, numerous alternative ETS members also can fuse to TMPRSS2, albeit at a much lower frequency. Similarly, variability in 5' partners have also been identified (Table 1). An intensive study examining ETV1 rearrangements found that only 9 of 23 samples had previously identified 5' partners, demonstrating the dramatic variability in fusion partners pairing with ETS transcription factors other than ERG (Attard et al., 2008b). The combined frequency of the remaining fusion variants accounts for approximately 10% of cases.

Five prime partners are divided into classes based on their tissue specificity and sensitivity to androgens (Tomlins et al., 2007). Class I is reserved for TMPRSS2; Class II represents other prostate-specific androgen inducible 5' UTR or endogenous retroviral elements; Class III represents the prostate-specific but androgen repressed partners; Class IV represents the non-tissue-specific promoters that are ubiquitously expressed, (i.e. house-keeping genes-this class often forms a chimeric or fusion protein, unlike the previous divisions of gene fusions); and finally Class V consists of ETV1-specific rearrangements, including the localization of the entire ETV1 locus to prostate specific locus, 14q13.3-14q21.1 (Tomlins et al., 2007; Attard et al., 2008b). To date only a single study has identified fusion genes in CaP devoid of ETS transcription factor participation (Palanisamy et al., 2010).

Table 1
5' partner
3' partner
Initial reference
Tomlins et al.(2005)
Tomlins et al. (2005)
Tomlins et al. (2006)
Tomlins et al. (2007)
Tomlins et al (2007)
Tomlins et al. (2007)
Tomlins et al. (2007)
Hermans et al. (2008a)
Hermans et al. (2008a)
Attard et al. (2008b)
Han et al. (2008)
Han et al. (2008)
Han et al. (2008)
Helgeson et al. (2008)
Helgeson et al. (2008)
Hermans et al. (2008b)
Hermans et al. (2008b)
Hermans et al. (2008b)
Rickman et al. (2009)
Pflueger et al. (2009)
ETS neg
Palanisamy et al. (2010)
ETS neg
Palanisamy et al. (2010)

*Only 3' partners identified to date that are not a member of the ETS transcription factor family.

VI. Detection and classification


Two strategies for FISH experiments are frequently used to detect the TMPRSS2:ERG fusion gene in CaP. The three-colour break-apart strategy, developed by Yoshimoto et al. (2006), uses differentially labelled bacterial artificial chromosome (BAC) clones as probes for the 3' (RP11-476D17) and 5' (RP11-95I21) segments of ERG with an additional BAC probe specific for the 5' region of TMPRSS2 (RP11-535H11) or for the transcriptional regulatory sequences (telomeric) of TMPRSS2 (RP11-35C4, RP11-891L10; RP11-260O11; Figure 1) (Yoshimoto et al., 2006). Using this probe configuration enables not only the detection of ERG rearrangement, but also allows confirmation that ERG's coding sequences are juxtaposed to the transcriptional regulatory region of TMPRSS2. Moreover, the mechanism of rearrangement can also be deduced by this approach (Yoshimoto et al., 2006; Yoshimoto et al., 2007). Characterization of rearrangement method is essential as differential clinical impacts are observed with the various mechanisms resulting in ETS gene fusions.

Figure 1: In house BAC probe configuration for three-colour break-apart TMPRSS2:ERG gene fusion FISH

This schematic ideogram depicts the positions of differentially labelled bacterial artificial chromosome (BAC) clones specific for 3' and 5' regions of the ERG gene (RP11-476D17 in spectrum orange and RP11-95I21 in spectrum green, respectively), within the 21q22.2-3 region. Telomeric to this, the TMPRSS2 gene locus is represented by RP11-535H11 (spectrum red) which spans the gene, or by three BAC clones downstream (telomeric) of the TMPRSS2 gene (RP11-35C4, RP11-891L10 and RP11-260O11 in spectrum aqua). This probe design permits the accurate identification of TMPRSS2:ERG gene fusions as well as ERG rearrangements independent of fusion with TMPRSS2 fusion.


Work by Attard and colleagues classified the TMPRSS2:ERG rearrangement mechanisms according to the pattern of interphase FISH signals (Attard et al., 2008a). Class N describes the normal ERG locus, therefore co-localization of the two ERG probe signals in close proximity to the TMPRSS2 signal (less than one signal diameter) (Figure 2A). The majority of fusion-positive cases present with a heterozygous deletion at cytoband 21q22.2-3, termed Class Edel (Figure 2B). The deletion typically spans ERG, exons 1-3 and a partial deletion of exon 4, the known intervening genes (based on RefSeq Genes: NCRNA00114, ETS2, PSMG1, BRWD1, NCRNA00257, HMGN1, WRB, LCA5L, SH3BGR, C21orf88, B3GALT5, IGSF5, PCP4, DSCAM, C21orf130, MIR3197, BACE2, PLAC4, FAM3B, MX2, and MX1) and the coding exons of TMPRSS2. The three-colour FISH of an Edel rearrangement displays co-localization of the 3' ERG and TMPRSS2 signals, and absence of the 5' ERG signal. Less frequently a genomic rearrangement leading to insertion of those sequences elsewhere in the genome to an unknown chromosome location can occur resulting in the separation of the 5' ERG signals from the co-localization of the 3' ERG and TMPRSS2 signals, thus described as ERG split or Class Esplit (Figure 2C). In both types of TMPRSS2:ERG rearrangements the unaffected chromosome 21 generally display a Class N signal configuration. Finally, additional copies of TMPRSS2:ERG gene fusions is identified as Class 2+Edel (Attard et al., 2008a).

Figure 2: Classification of TMPRSS2:ERG gene fusion by interphase FISH.

Prostate cancer patient samples were hybridized with the three-colour probe set, described in Figure 1, and counterstained with DAPI. The nuclei of interest (in dashed boxes) are magnified in the insets. A) Class N, where no ERG rearrangement has occurred. Co-localization of 3' and 5' ERG probes (often visualized as a yellow signal), with the 5' TMPRSS2 BAC probe signals (red) indicates a normal Chr21q22.2-3 locus. Frequently, the signals for the TMPRSS2 probe, situated 2.7 Mb away from the ERG locus, may be separated from the ERG signals by up to one probe signal width. B) Class Edel is characterized by the co-localization of 3' ERG probe to the TMPRSS2 probe signals, and the absence of the 5' ERG signal. This represents rearrangement with the loss of the intervening sequence. The unaffected Chr21 displays Class N configuration. C) Class Esplit is characterized by the co-localization of the 3' ERG and TMPRSS2 signals, with the retention of the 5' ERG signal elsewhere in the nucleus. The unaffected Chr21 displays Class N configuration.


The second strategy employs a two-colour break-apart FISH design to identify rearrangements in specific ETS genes (Mehra et al., 2007; Zhang et al., 2010). By this method, confirmation of fusion between two genes and identification of the specific 5' partner is not possible because the probes are specific for a single gene, and therefore, this strategy is an indirect method for the detection of fusion genes in CaP.

VI.ii. Other methods of detection

RT-PCR is another technique frequently employed to determine the fusion status of prostatic tissue samples. However, this approach is limited to the detection of the hybrid transcripts, and is unable to obtain important cytogenetic information such as the genomic mechanism that generated the gene fusion (Edel vs Esplit). To date, as many as 17 fusion transcripts and splice variations have been characterized, the most common fusion transcript is composed of exon 1 of TMPRSS2 fused to exon 4 of ERG (T1:E4 (Wang et al., 2006; Jhavar et al., 2008)). The majority of the remaining transcripts result in truncation of the ERG protein product by 39-99 amino acids, while the few that initiate translation from the native start codon in exon 3 produce full length ERG (Tomlins et al., 2005; Soller et al., 2006; Wang et al., 2006; Clark et al., 2007; Clark et al., 2008a). One of the transcripts produces a genuine TMPRSS2:ERG fusion protein and eight contain premature stop codons and are unlikely to result in ERG overexpression (Tomlins et al., 2005; Soller et al., 2006; Wang et al., 2006; Clark et al., 2007; Clark et al., 2008a). These studies further revealed that elaborate heterogeneity exists in hybrid transcripts present, between foci and within individual tumour foci of the same patient. Variability in the translation start site consequentially affects the size of the mRNA transcript (373-885 bp) and therefore the protein product potentially modifying the functional capacity of the gene fusion product (Wang et al., 2006). Distinct transcript variants display differential prognostic influence based on the resultant biological activities (Hermans et al., 2009; Wang et al., 2008). A significant challenge remains in relating the clinical prognosis to the fusion gene and will be addressed in the subsequent section.

Indirect methods suggestive of gene fusions in CaP are being employed to broadly determine ETS rearrangement status with perhaps the anticipation of implementing a high-throughput method of detection. Analysis of array comparative genomic hybridization (aCGH) data, specifically the 21q22.2-3 region may permit identification of Class Edel TMPRSS2:ERG gene fusions (Watson et al., 2009; Ishkanian et al., 2009). Class Esplit retains the intervening sequences within the nuclei, in a copy neutral manner and consequently aCGH cannot identify this rearrangement. Overexpression of ETS transcription factors by gene expression microarrays may also imply an ETS rearrangement has occurred. Due to inconclusive results, FISH or RT-PCR assays are necessary to validate microarray findings pertaining to the ETS gene fusions. A novel multiplexing technology recently developed uses nanostructured microelectrodes integrated onto a chip and has the capability to detect disease-specific biomarkers, including differentiation of various fusion transcripts (Fang et al., 2009). More recently, immunohistochemistry (IHC) is also being explored as a means to detect the fusion by ERG protein overexpression, in the absence of confirming fusion at the genomic or transcript level (Furusato et al., 2010; Park et al., 2010). Of the numerous direct (three-colour FISH, RT-PCR) and indirect (two-colour FISH, microarrays, IHC) methods employed to determine fusion status to date, the three-colour FISH yields the most cytogenetic and genomic information. In addition, to identifying the fusion status and class, the inherent cell-by-cell analysis addresses the heterogeneous nature of the disease, and provides a biological context for such information.

VII. Fusion gene formation and chromosomal instability

There is increasing research interest and effort focusing on the genomic events and attributes that lead to the formation of ETS gene fusions. A complex TMPRSS2:ERG rearrangement found in a single patient was meticulously examined and described by Yoshimoto et al. (2007). This patient had a microdeletion of the sequences from 5' ERG to and including the TMPRSS2 coding sequences with a concurrent translocation of the region immediately telomeric of 5' untranslated TMPRSS2 sequences. A detailed multicolour FISH assay mapped the region between ERG and TMPRSS2, revealing the complexity of chromosomal rearrangements that can lead to the formation of fusion genes in CaP. This case demonstrates the valuable information available through the use of complex multicolour FISH assays.

The molecular mechanisms that underlie this recurrent translocation are just beginning to be understood. For example, fine mapping of the deletion breakpoints located within the ERG and TMPRSS2 loci, followed by sequencing, revealed the presence of consensus sequences homologous to the human Alu-Sq and Alu-Sp subfamily (Liu et al., 2006). The presence of these consensus sequences within intronic regions correlated with the presence of the fusion gene and may be a factor contributing to the deletion at 21q22.2-3, resulting in the fusion gene. More recently, genotyping of familial CaP revealed that the fusion gene associates with polymorphisms in DNA repair genes, specifically POLI and ESCO1 (Luedeke et al., 2009).

Using FISH, the AR was shown to induce chromosomal proximity of TMPRSS2 and ERG by binding to the promoter region of TMPRSS2 (Mani et al., 2009). Subsequently, LnCaP cells were irradiated to induce double-strand breaks inducing the formation of the TMPRSS2:ERG gene fusion upon dihydrotestosterone stimulation in the previously fusion-negative cell line (Mani et al., 2009). The DNA-bound AR is also implicated in chromatin architecture modifications that can cause double-strand breaks, commonly repaired by non homologous end joining machinery, and may result in the formation of gene fusions (Lin et al., 2009). Also recently, androgen signalling was shown to recruit topoisomerase II beta with the AR to the breakpoints resulting TMPRSS2:ERG fusion genes (Haffner et al., 2009). Undoubtedly, specific nucleotide sequences within the 21q22.2-3 region are of great importance and further elucidation as to their role in the formation of gene fusions is essential. The TMPRSS2:ERG gene fusion is an unique model to query sequence level polymorphisms that may lead to the formation of intra-chromosomal rearrangements largely due to the close proximity and orientation of the involved genes as well as the high rate of recurrence.

Chromosomal instability, defined as the formation of novel chromosome alterations and rearrangements at an elevated rate, compared to normal cells may also be a factor contributing to the formation of ETS gene fusions in CaP. It is well established that deletion of the tumour suppressor PTEN (10q23.31), a common genomic aberration in CaP, results in an elevated level of chromosomal instability through activation of AKT. One of sequelae of this change is the phosphorylation and inhibition of the cell cycle check point kinase 1 (Chk1), an important kinase preventing cell cycle progression in response to DNA damage (Puc et al., 2005; Sanchez et al., 1997). Furthermore, nuclear PTEN interacts with kinetochore proteins and induces the expression of RAD51, a protein required to reduce the incidence of spontaneous double-strand breaks (Shen et al., 2007). PTEN deficiency ultimately alters multiple cell cycle checkpoints, which could potentially delay DNA damage repair and/or chromosome segregation (Gupta et al., 2009). Overall, PTEN has a variety of roles in maintaining chromosomal stability and integrity, and the recurrent PTEN loss in CaP may represent an important trigger in the events leading to the formation of TMPRSS2:ETS gene fusions.

VIII. Heterogeneity of multifocal disease

CaP, one of the most heterogeneous epithelial carcinomas, is also notoriously multifocal in nature. As a multifocal disease, CaP permits the investigation and comparison of recurrent genomic events within distinct foci of individual patients. In 32 RP specimens with spatially distinct foci, ERG rearrangement status was examined using two-colour FISH (Barry et al., 2007). Nineteen samples displayed interfocal homogeneity, with 80% of the samples negative for ERG rearrangement. The remaining 13 samples exhibited interfocal heterogeneity but intrafocal homogeneity, with two samples harbouring three separate foci each with a different rearrangement status: Class N, Edel and Esplit. Similarly, whole mount examination of RP specimens for fusion transcripts yielded multiple fusion transcripts in individual CaP foci with an identical hybrid transcript profile in the adjacent HGPIN (Furusato et al., 2008). Two other studies examining fusion transcript variants found different transcript hybrids in discrete regions of a single prostate (Wang et al., 2006; Clark et al., 2007). Multiple TMPRSS2:ETS gene fusion-positive foci may arise independently and exhibit interfocal heterogeneity. Investigation of ERG rearrangement in multifocal CaP and corresponding metastases provides a glimpse of the potential biological impact of this aberration in the context of disease progression (Perner et al., 2009). This study reported that the metastatic lesion was always positive for ERG rearrangement through the same mechanism (Edel vs Esplit) as that present in at least one of the prostatic tumour foci (not necessarily the index focus). The authors suggest that this rearrangement may be a factor contributing to the development of metastases, regardless of clinicopathological criteria of the individual foci.

IX. Prognostic significance

There exists appreciable controversy with respect to the prognostic significance of the TMPRSS2:ERG gene fusion in CaP, with studies suggesting that the fusion gene has a favourable (Winnes et al., 2007; Petrovics et al., 2005; Winnes et al., 2007; Saramaki et al., 2008), unfavourable (Yoshimoto et al., 2008; Mehra et al., 2007a; Perner et al., 2006; Wang et al., 2006; Nam et al., 2007a; Nam et al., 2007b; Attard et al., 2008a; Mehra et al., 2008; Reid et al., 2010; Demichelis et al., 2007; Rostad et al., 2009; Lapointe et al., 2007a) or no association (Mehra et al., 2008; Yoshimoto et al., 2006; Neill et al., 2007; Fletcher et al., 2008; Dai et al., 2008; Furusato et al., 2008; Darnel et al., 2009; Gopalan et al., 2009; Rubio-Briones et al., 2010; Fitzgerald et al., 2008; Lee et al., 2010; Sun et al., 2010; Rouzier et al., 2008) with clinical outcomes. When no association between clinicopathological criteria and the presence of the fusion gene was found, it was often attributable to small sample sizes. The most compelling evidence suggests a trend towards unfavourable factors outcome in CaP progression. Notably, an interesting comparison of two studies looking at conservatively managed men had opposing results from an association with CaP-specific death (Demichelis et al., 2007) to no reduction in CaP-specific survival for patients harbouring this rearrangement (Fitzgerald et al., 2008).

The role of deletion (Edel) or retention (Esplit) of intervening sequences in tumour biology has also been scrutinized with relatively uniform results suggesting that Edel is not only the more prevalent mechanism but is also associated with more aggressive disease (Mwamukonda et al., 2010; Attard et al., 2008a; Mehra et al., 2008). Edel was associated with worse prostate-specific survival and shorter time to biochemical recurrence than Class Esplit (Yoshimoto et al., 2006; Attard et al., 2008a). While, Class 2+Edel was associated with lethal disease and significantly worse clinical outcome, particularly when combined with prostate-specific clinicopathological criteria (Yoshimoto et al., 2006; Attard et al., 2008a). Another study also demonstrated that Edel rearrangements have a more aggressive tendency since all fusion-positive androgen-independent metastases had lost 5' ERG sequences (Mehra et al., 2008) and Edel was associated with clinically aggressive features of progression (Perner et al., 2006). These findings are consistent with elevated ERG expression and led investigators to speculate that the loss of 5' ERG is associated with aggressive CaP.

It must be considered that the commonly deleted 2.7 Mb between ERG and TMPRSS2 could contain important tumour suppressor genes (Yoshimoto et al., 2006) and its loss in the Edel rearrangement leads to haploinsufficiency of a tumour suppressor gene that underlies the aggressive clinical course. One gene candidate for this effect within this region, HMGN1, a nucleosome binding protein has previously been associated with CaP progression (Birger et al., 2005). In agreement with this view, the Esplit rearrangement has not yet been shown to associate with any particular clinical outcome to date. However, given the low frequency of this event (~10% of TMPRSS2:ERG rearrangements), Esplit rearrangements cannot be excluded as a measure of prognosis until further studies are completed (Attard et al., 2008a).

On the other hand, one investigation demonstrated no statistically significant association with clinicopathological criteria and Edel or Esplit, but evidence did suggest 2+Edel is a factor contributing to CaP-specific mortality (Fitzgerald et al., 2008). Conversely, TMPRSS2:ERG rearrangement alone were associated with lower histological grade, but no other clinical features or CaP-specific death (Gopalan et al., 2009). However, the same group also found that copy number increases (CNI) of the ERG locus with or without TMPRSS2:ERG gene fusions was associated with high grade and advanced stage, while cancers with CNI and 2+Edel rearrangements tended to be more clinically aggressive (Fine et al., 2010). While the above results are conflicting to the previous studies that showed no association with extra copies of the unrearranged ERG locus (Attard et al., 2008a), the difference may be due to the deletion of the intervening genes potentially generating a more aggressive tumourigenic phenotype.

SPINK1 (5q32) is a gene identified in a more recent COPA meta-analysis as being overexpressed in 10% of CaP, all of which are exclusively ETS fusion negative (Tomlins et al., 2008b). For this reason, SPINK1 expression and the TMPRSS2:ERG fusion gene were evaluated to determine their relative significance as prognostic biomarkers in biopsy samples from hormonally treated men (Leinonen et al., 2010). In this cohort, the fusion gene was associated with Ki-67 staining, age at diagnosis and tumour area, but not with any prostate-specific clinicopathological criteria (Leinonen et al., 2010). On the other hand, cases that overexpressed SPINK1 had a significantly shorter time to biochemical recurrence, but no association with any other criteria.

X. Clinical utility

Promptly following the emergence of adverse clinical correlations of fusion-positive CaP Mosquera and colleagues evaluated a series of CaP cases to determine if there was a morphological phenotype associated with this genomic alteration (Mosquera et al., 2007). Blinded to ERG rearrangement status, the group identified five histologic criteria that were significantly related to ERG rearrangement positive samples: blue-tinged mucin, cribriform growth, macronucleoli, intraductal tumour spread, and signet-ring cell features. Only 24% of ERG rearranged samples did not identify with any of the above mentioned morphological features and 93% of samples with three features were positive for ERG rearrangement. The authors speculate that the morphological characteristics shared by ERG rearranged tumours could result from ETS dysregulated pathways and could be utilized in the routine assessment performed by pathologists. More recently, the same group published a similar set of morphological features with the addition of collagenous micronodules (Mosquera et al., 2009). A significant association between perineural invasion, blue-tinged mucin, and intraductal tumor spread with a positive gene fusion status has been documented (Nigwekar et al., 2008), while another study confirmed the association that ETS fusion-positive CaP samples were more likely mucin-positive than mucin-negative (Tu et al., 2007). These results should be taken, however, in the context of somewhat contradictory reports, such that the TMPRSS2:ERG gene fusion correlates with low Gleason grade and is inversely related to high-grade morphological features. These studies hold promise that morphological markers routinely examined by pathologists could be coupled with the current clinicopathological criteria for a more comprehensive evaluation of biopsy or RP specimens providing well-informed judgments on diagnosis, prognosis and treatment decisions.

In an attempt to optimize the clinical utility of this biomarker, investigators are turning to less invasive survey modes, such as urine specimens and circulating tumour cells (CTCs). Post-digital rectal exam (DRE) urine analyzed by qRT-PCR found 17.2% positive rate for ERG overexpression. Subsequent examination of the corresponding biopsy samples from the same cohort revealed a 40% positive rate (Rice et al., 2010). The clinical yield of this assay can be improved, as indicated by another study which found a 69% positive rate following prostatic message versus only 24% when no prostatic message was performed before collecting the urine samples (Rostad et al., 2009). Two additional studies report similar results (42% and 59%) of fusion-positive transcripts in post-DRE urine (Hessels et al., 2007; Laxman et al., 2006). Expressed prostatic secretion has also been a successful specimen for the non-invasive detection of fusion transcripts (Clark et al., 2008b). These studies demonstrate the potential for ETS gene fusion detection using non-invasive approaches following physical evaluation of the prostate by DRE, adding valuable information to disease stratification prior to radical treatments. A handful of studies have also used FISH to detect ERG rearrangement in CTCs in effort to monitor disease recurrence or treatment efficacy (Mao et al., 2008; Attard et al., 2009; Stott et al., 2010).

XI. Role of ETS in prostate tumourigenesis: Driver?

Discrepancies regarding the fusion gene are not limited to its diagnostic potential and prognostic significance. Controversy also exists in the sequence of genomic and molecular alterations in CaP initiation and progression. Several groups speculate that the formation of the TMPRSS2:ERG fusion gene is required for CaP initiation in ETS positive CaP tumours, with other aberrations occuring later in the course of disease advancement and metastasis (Perner et al., 2007; Tomlins et al., 2007; Attard et al., 2009). Recently, Attard and colleagues demonstrated that CTCs from individual castration-resistant CaP patients were either clonally positive or negative for ERG rearrangement, however, loss of PTEN and increase in AR gene copy number was heterogeneous in the CTCs derived from a single patient (Attard et al., 2009). These results suggest that the formation of the fusion gene occurred before PTEN loss and gain of the AR locus. However, this study was performed on a very small cohort of castration-resistant CaP and may not necessarily reflect the sequence of accumulating genomic alterations in CaP.

TMPRSS2:ETS fusion status in HGPIN occurs at a low frequency, and almost exclusively only when juxtaposed to fusion-positive CaP. These HGPIN lesions, however, do not exhibit the chromosomal copy number changes seen in 42% of the paired CaP as assessed by CGH (Cerveira et al., 2006). These results propose that formation of the fusion gene may precede chromosomal-level alterations and is consistent with the literature indicating that few gross chromosome- or arm-level chromosomal copy alterations are present in localized CaP. Another study investigating a range of prostate tissues comprising benign, precursor, malignant and metastatic samples found that the majority of patient samples examined showed homogeneity with respect to fusion status and mechanism (Edel vs Esplit). The presence of fusion-positive HGPIN was interpreted as additional evidence that this entity is a true-precursor to CaP, a notion that has eluded indisputable proof (Perner et al., 2007). In contrast, a recent study that examined both PTEN genomic loss and fusion status by FISH observed PTEN loss in benign and HGPIN lesions, while ERG rearrangement was identified in HGPIN, albeit at a lower frequency than PTEN loss, and absent in BPH lesions (Bismar et al., 2010). Maintaining this model of progression and accumulation of genomic changes in CaP it is possible that heterozygous loss of PTEN may be a 'driver lesion', in a subset of CaP, and PTEN haploinsufficiency may facilitate the selective formation of the fusion gene (Figure 3). TMPRSS2:ERG gene fusion may occur as a secondary alteration and may function as an 'enhancer' permitting the cell to achieve a higher level of aggressiveness and invasiveness. When this sequence of events was emulated in transgenic mice, ERG overexpression resulted in marked acceleration of preneoplastic lesions to invasive CaP on a Pten deleted background, but ERG overexpression alone simply displayed slight atypical histology compared to control mice (Carver et al., 2009a; Carver et al., 2009b). In vitro experiments using cell lines demonstrated ERG overexpression provided enhanced motility without affecting proliferation, in agreement with Tomlins et al. (2007); Carver et al. (2009b). These findings corroborate the view that effectors of ERG overexpression affect cellular processes which are complimentary to unregulated factors downstream of AKT as a result of PTEN deficiency, but on their own are not sufficient to provoke the transition from benign to neoplastic. The implication is not that PTEN loss is the driver in CaP, but that ETS gene fusions are enhancer alterations significantly affecting cellular processes further progressing prostatic tumourigenesis when the background is primed first by a driver event capable of initiating sufficient dysregulation leading to the development of a preneoplastic lesion. However, because PTEN loss and the presence of the fusion gene are significantly associated events in CaP (Yoshimoto et al., 2008; Carver et al., 2009a; Han et al., 2009; King et al., 2009; Bismar et al., 2010) it is likely that PTEN inactivation may be an important driver lesion for fusion-positive CaP. Together the driver event and ETS overexpression lead to a significantly aggressive and invasive lesion. Therefore, elucidation of the cellular pathways affected by ETS overexpression is fundamental to the comprehension of the aggressive nature observed in the majority of fusion-positive CaP, and to developing novel therapeutic strategies to specifically target this subset of CaP.

Figure 3: Model of prostate cancer progression showing ETS gene fusions as an enhancer lesion.

Cooperation of unregulated pathways downstream of PTEN with effectors of ERG overexpression is likely a crucial event in the progression of an invasive and aggressive prostatic adenocarcinoma. Heterozygous genomic deletion of PTEN in benign prostatic precursors may represent an early event, and act as a driver lesion leading to proliferation, survival and genomic instability-all initial requisites of cancer. As a consequence of such heightened genomic instability, PTEN haploinsufficiency may facilitate the selective formation of the fusion gene with consequent acquisition of additional invasive properties. The presence of both rearrangements within a lesion is associated with accelerated disease progression and poor prognosis, indicating that synergistic molecular interactions exist between their complementary pathways. Continuing instability generates genotypic heterogeneity and diversity, such that subclones bearing PTEN homozygous deletions and amplified AR loci have further selective advantage for aggressive tumour progression, androgen escape and metastases.

XII. Concluding remarks

Difficulty in assigning prognostic significance, diagnostic and therapeutic utility to ETS gene fusions is a result of a myriad of factors including, the heterogeneity of the disease, the mechanism of rearrangement (Edel vs Esplit), the technique used to assess the presence of the fusion as well as the cohort examined. Nevertheless, continued controversy between positive and negative clinical associations of the gene fusion dictates further studies are required using larger cohorts to determine the absolute potential of this genomic aberration as a biomarker for CaP diagnostic utility, prognostic significance, and stratification of patients to aid in treatment decisions. Furthermore, comprehension of the pathways affected by ETS overexpression will aid in the potential of implementing ETS specific therapies to target this aggressive subtype of CaP and benefit many patients.



The erg gene: a human gene related to the ets oncogene.
Reddy ES, Rao VN, Papas TS.
Proc Natl Acad Sci U S A. 1987 Sep;84(17):6131-5.
PMID 3476934
erg, an ets-related gene, codes for sequence-specific transcriptional activators.
Reddy ES, Rao VN.
Oncogene. 1991 Dec;6(12):2285-9.
PMID 1766675
Interaction of murine ets-1 with GGA-binding sites establishes the ETS domain as a new DNA-binding motif.
Nye JA, Petersen JM, Gunther CV, Jonsen MD, Graves BJ.
Genes Dev. 1992 Jun;6(6):975-90.
PMID 1592264
The Ets transcription factors interact with each other and with the c-Fos/c-Jun complex via distinct protein domains in a DNA-dependent and -independent manner.
Basuyaux JP, Ferreira E, Stehelin D, Buttice G.
J Biol Chem. 1997 Oct 17;272(42):26188-95.
PMID 9334186
Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3.
Paoloni-Giacobino A, Chen H, Peitsch MC, Rossier C, Antonarakis SE.
Genomics. 1997 Sep 15;44(3):309-20.
PMID 9325052
Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25.
Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, Elledge SJ.
Science. 1997 Sep 5;277(5331):1497-501.
PMID 9278511
Erg proteins, transcription factors of the Ets family, form homo, heterodimers and ternary complexes via two distinct domains.
Carrere S, Verger A, Flourens A, Stehelin D, Duterque-Coquillaud M.
Oncogene. 1998 Jun 25;16(25):3261-8.
PMID 9681824
Ets factors and regulation of the extracellular matrix.
Trojanowska M.
Oncogene. 2000 Dec 18;19(55):6464-71. (REVIEW)
PMID 11175362
Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia.
Afar DE, Vivanco I, Hubert RS, Kuo J, Chen E, Saffran DC, Raitano AB, Jakobovits A.
Cancer Res. 2001 Feb 15;61(4):1686-92.
PMID 11245484
c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells.
Chai Y, Chipitsyna G, Cui J, Liao B, Liu S, Aysola K, Yezdani M, Reddy ES, Rao VN.
Oncogene. 2001 Mar 15;20(11):1357-67.
PMID 11313879
Combined genomic and antisense analysis reveals that the transcription factor Erg is implicated in endothelial cell differentiation.
McLaughlin F, Ludbrook VJ, Cox J, von Carlowitz I, Brown S, Randi AM.
Blood. 2001 Dec 1;98(12):3332-9.
PMID 11719371
Role of ETS family transcription factors in vascular development and angiogenesis.
Sato Y.
Cell Struct Funct. 2001 Feb;26(1):19-24. (REVIEW)
PMID 11345500
The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease.
Vaarala MH, Porvari K, Kyllonen A, Lukkarinen O, Vihko P.
Int J Cancer. 2001 Dec 1;94(5):705-10.
PMID 11745466
Identification of amino acid residues in the ETS transcription factor Erg that mediate Erg-Jun/Fos-DNA ternary complex formation.
Verger A, Buisine E, Carrere S, Wintjens R, Flourens A, Coll J, Stehelin D, Duterque-Coquillaud M.
J Biol Chem. 2001 May 18;276(20):17181-9. Epub 2001 Feb 23.
PMID 11278640
ETS proteins and MMPs: partners in invasion and metastasis.
Singh S, Barrett J, Sakata K, Tozer RG, Singh G.
Curr Drug Targets. 2002 Oct;3(5):359-67. (REVIEW)
PMID 12182227
Understanding and appreciating overdiagnosis in the PSA era.
Yao SL, Lu-Yao G.
J Natl Cancer Inst. 2002 Jul 3;94(13):958-60.
PMID 12096074
Molecular biology of the Ets family of transcription factors.
Oikawa T, Yamada T.
Gene. 2003 Jan 16;303:11-34. (REVIEW)
PMID 12559563
Increased tumorigenicity and sensitivity to ionizing radiation upon loss of chromosomal protein HMGN1.
Birger Y, Catez F, Furusawa T, Lim JH, Prymakowska-Bosak M, West KL, Postnikov YV, Haines DC, Bustin M.
Cancer Res. 2005 Aug 1;65(15):6711-8.
PMID 16061652
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome.
Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y, Nau M, Ravindranath L, Chen Y, Dobi A, Srikantan V, Sesterhenn IA, McLeod DG, Vahey M, Moul JW, Srivastava S.
Oncogene. 2005 May 26;24(23):3847-52.
PMID 15750627
Lack of PTEN sequesters CHK1 and initiates genetic instability.
Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, Memeo L, Mansukhani M, Murty VV, Gaciong Z, Meek SE, Piwnica-Worms H, Hibshoosh H, Parsons R.
Cancer Cell. 2005 Feb;7(2):193-204.
PMID 15710331
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM.
Science. 2005 Oct 28;310(5748):644-8.
PMID 16254181
The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells.
Wilson S, Greer B, Hooper J, Zijlstra A, Walker B, Quigley J, Hawthorne S.
Biochem J. 2005 Jun 15;388(Pt 3):967-72.
PMID 15537383
TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions.
Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jeronimo C, Teixeira MR.
Neoplasia. 2006 Oct;8(10):826-32.
PMID 17032499
TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, Peltola M, Smit F, Verhaegh G, Schalken J, Nees M, Kallioniemi O.
Cancer Res. 2006 Nov 1;66(21):10242-6.
PMID 17079440
Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM.
Neoplasia. 2006 Oct;8(10):885-8.
PMID 17059688
Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array.
Liu W, Chang B, Sauvageot J, Dimitrov L, Gielzak M, Li T, Yan G, Sun J, Sun J, Adams TS, Turner AR, Kim JW, Meyers DA, Zheng SL, Isaacs WB, Xu J.
Genes Chromosomes Cancer. 2006 Nov;45(11):1018-32.
PMID 16897747
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.
Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA.
Cancer Res. 2006 Sep 1;66(17):8337-41.
PMID 16951139
Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer.
Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I.
Genes Chromosomes Cancer. 2006 Jul;45(7):717-9.
PMID 16575875
Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.
Terry S, Yang X, Chen MW, Vacherot F, Buttyan R.
J Cell Biochem. 2006 Oct 1;99(2):402-10. (REVIEW)
PMID 16741972
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.
Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, Chinnaiyan AM.
Cancer Res. 2006 Apr 1;66(7):3396-400.
PMID 16585160
Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.
Wang J, Cai Y, Ren C, Ittmann M.
Cancer Res. 2006 Sep 1;66(17):8347-51.
PMID 16951141
Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, Evans AJ, Zielenska M, Squire JA.
Neoplasia. 2006 Jun;8(6):465-9.
PMID 16820092
TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.
Barry M, Perner S, Demichelis F, Rubin MA.
Urology. 2007 Oct;70(4):630-3.
PMID 17991527
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate.
Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, Eeles R, Martin FL, Phillips DH, Crundwell M, Christmas T, Thompson A, Fisher C, Kovacs G, Cooper CS.
Oncogene. 2007 Apr 19;26(18):2667-73. Epub 2006 Oct 16.
PMID 17043636
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.
Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA.
Oncogene. 2007 Jul 5;26(31):4596-9. Epub 2007 Jan 22.
PMID 17237811
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA.
Clin Cancer Res. 2007 Sep 1;13(17):5103-8.
PMID 17785564
A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.
Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn M, Huntsman DG, Brooks JD, Pollack JR.
Mod Pathol. 2007a Apr;20(4):467-73. Epub 2007 Mar 2.
PMID 17334351
Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis.
Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, Pollack JR.
Cancer Res. 2007b Sep 15;67(18):8504-10.
PMID 17875689
Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.
Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM, Shah RB.
Cancer Res. 2007a Sep 1;67(17):7991-5.
PMID 17804708
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.
Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB.
Mod Pathol. 2007b May;20(5):538-44. Epub 2007 Mar 2.
PMID 17334343
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.
Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA, Squire JA.
Br J Cancer. 2007 Sep 3;97(5):678-85. Epub 2007 Aug 14.
PMID 17700571
Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA.
J Pathol. 2007 May;212(1):91-101.
PMID 17385188
Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression.
Nam RK, Sugar L, Wang Z, Yang W, Kitching R, Klotz LH, Venkateswaran V, Narod SA, Seth A.
Cancer Biol Ther. 2007a Jan;6(1):40-5.
PMID 17172822
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer.
Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, Stanimirovic A, Encioiu E, Neill M, Loblaw DA, Trachtenberg J, Narod SA, Seth A.
Br J Cancer. 2007b Dec 17;97(12):1690-5. Epub 2007 Oct 30.
PMID 17971772
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.
Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA.
Am J Surg Pathol. 2007 Jun;31(6):882-8.
PMID 17527075
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.
Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, Cox ME, Huntsman DG.
J Clin Pathol. 2007 Nov;60(11):1238-43. Epub 2007 Jan 26.
PMID 17259299
Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data.
Rouzier C, Haudebourg J, Carpentier X, Valerio L, Amiel J, Michiels JF, Pedeutour F.
Cancer Genet Cytogenet. 2008 May;183(1):21-7.
PMID 18474293
Essential role for nuclear PTEN in maintaining chromosomal integrity.
Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, Yin Y.
Cell. 2007 Jan 12;128(1):157-70.
PMID 17218262
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM.
Nature. 2007 Aug 2;448(7153):595-9.
PMID 17671502
Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.
Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S, Chen YT.
Mod Pathol. 2007 Sep;20(9):921-8. Epub 2007 Jul 13.
PMID 17632455
Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M, Lissbrant E, Damber JE, Stenman G.
Oncol Rep. 2007 May;17(5):1033-6.
PMID 17390040
Absence of fusion of TMPRSS2 and ETS transcription factor genes in gastric and colorectal carcinomas.
Yoo NJ, Lee JW, Lee SH.
APMIS. 2007 Mar;115(3):252-3.
PMID 17367471
Microdeletion and concurrent translocation associated with a complex TMPRSS2:ERG prostate cancer gene fusion.
Yoshimoto M, Ludkovski O, Bayani J, Graham C, Zielenska M, Squire JA.
Genes Chromosomes Cancer. 2007 Sep;46(9):861-3.
PMID 17584912
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.
Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J, Cooper CS; Transatlantic Prostate Group.
Oncogene. 2008a Jan 10;27(3):253-63. Epub 2007 Jul 16.
PMID 17637754
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer.
Attard G, Clark J, Ambroisine L, Mills IG, Fisher G, Flohr P, Reid A, Edwards S, Kovacs G, Berney D, Foster C, Massie CE, Fletcher A, De Bono JS, Scardino P, Cuzick J, Cooper CS; Transatlantic Prostate Group.
Br J Cancer. 2008b Jul 22;99(2):314-20. Epub 2008 Jul 1.
PMID 18594527
AR, the cell cycle, and prostate cancer.
Balk SP, Knudsen KE.
Nucl Recept Signal. 2008 Feb 1;6:e001. (REVIEW)
PMID 18301781
Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin.
Birdsey GM, Dryden NH, Amsellem V, Gebhardt F, Sahnan K, Haskard DO, Dejana E, Mason JC, Randi AM.
Blood. 2008 Apr 1;111(7):3498-506. Epub 2008 Jan 14.
PMID 18195090
Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Bjorkman M, Iljin K, Halonen P, Sara H, Kaivanto E, Nees M, Kallioniemi OP.
Int J Cancer. 2008 Dec 15;123(12):2774-81.
PMID 18798265
Complex patterns of ETS gene alteration arise during cancer development in the human prostate.
Clark J, Attard G, Jhavar S, Flohr P, Reid A, De-Bono J, Eeles R, Scardino P, Cuzick J, Fisher G, Parker MD, Foster CS, Berney D, Kovacs G, Cooper CS.
Oncogene. 2008a Mar 27;27(14):1993-2003. Epub 2007 Oct 8.
PMID 17922029
Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.
Clark JP, Munson KW, Gu JW, Lamparska-Kupsik K, Chan KG, Yoshida JS, Kawachi MH, Crocitto LE, Wilson TG, Feng Z, Smith SS.
Clin Chem. 2008b Dec;54(12):2007-17. Epub 2008 Oct 23.
PMID 18948370
[Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
Dai MJ, Chen LL, Zheng YB, Chen W, Tao ZH, Weng ZL, Wu XL, Li CD, Chen ZG, Chen XD, Shi SB.
Zhonghua Yi Xue Za Zhi. 2008 Mar 11;88(10):669-73.
PMID 18642766
Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.
FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL, Huntsman DG.
BMC Cancer. 2008 Aug 11;8:230.
PMID 18694509
Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA.
Mod Pathol. 2008 Feb;21(2):67-75. Epub 2007 Dec 7.
PMID 18065961
A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.
Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ, Wang X, Gong Y, Wang L, Shankar S, Laxman B, Shah RB, Varambally S, Palanisamy N, Tomlins SA, Kumar-Sinha C, Chinnaiyan AM.
Cancer Res. 2008 Sep 15;68(18):7629-37.
PMID 18794152
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, Mehra R, Chinnaiyan AM.
Cancer Res. 2008 Jan 1;68(1):73-80.
PMID 18172298
Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer.
Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, Trapman J.
Cancer Res. 2008a May 1;68(9):3094-8.
PMID 18451133
Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer.
Hermans KG, van der Korput HA, van Marion R, van de Wijngaart DJ, Ziel-van der Made A, Dits NF, Boormans JL, van der Kwast TH, van Dekken H, Bangma CH, Korsten H, Kraaij R, Jenster G, Trapman J.
Cancer Res. 2008b Sep 15;68(18):7541-9.
PMID 18794142
Delineation of TMPRSS2-ERG splice variants in prostate cancer.
Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L, Cullen J, Furusato B, Chen Y, Thangapazham RL, Mohamed A, Sun C, Sesterhenn IA, McLeod DG, Petrovics G, Srivastava S.
Clin Cancer Res. 2008 Aug 1;14(15):4719-25.
PMID 18676740
Cancer statistics, 2008.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ.
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. Epub 2008 Feb 20.
PMID 18287387
Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays.
Jhavar S, Reid A, Clark J, Kote-Jarai Z, Christmas T, Thompson A, Woodhouse C, Ogden C, Fisher C, Corbishley C, De-Bono J, Eeles R, Brewer D, Cooper C.
J Mol Diagn. 2008 Jan;10(1):50-7. Epub 2007 Dec 28.
PMID 18165275
A causal role for ERG in neoplastic transformation of prostate epithelium.
Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, Nelson PS, Vasioukhin V.
Acad Sci U S A. 2008 Feb 12;105(6):2105-10. Epub 2008 Feb 1.
PMID 18245377
Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells.
Mao X, Shaw G, James SY, Purkis P, Kudahetti SC, Tsigani T, Kia S, Young BD, Oliver RT, Berney D, Prowse DM, Lu YJ.
Asian J Androl. 2008 May;10(3):467-73.
PMID 18385909
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM.
Cancer Res. 2008 May 15;68(10):3584-90.
PMID 18483239
Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.
Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G, Shah RB, Loda M, Rubin MA.
Clin Cancer Res. 2008 Jun 1;14(11):3380-5.
PMID 18519767
Morphologic correlates of individual splice variants of TMPRSS2-ERG prostate cancer (PCa) detected by transcription-mediated amplification (TMA) in radical prostatectomy (RP) specimens [abstract 797].
Nigwekar P, Miick S, Rittenhouse H, et al.
in USCAP, 2008. Denver (CO).
TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T.
Clin Cancer Res. 2008 Jun 1;14(11):3395-400.
PMID 18519769
The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.
Schweizer L, Rizzo CA, Spires TE, Platero JS, Wu Q, Lin TA, Gottardis MM, Attar RM.
BMC Cell Biol. 2008 Jan 24;9:4.
PMID 18218096
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.
Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, Shaheduzzaman S, Tan SH, Vaidyanathan G, Whitman E, Hawksworth DJ, Chen Y, Nau M, Patel V, Vahey M, Gutkind JS, Sreenath T, Petrovics G, Sesterhenn IA, McLeod DG, Srivastava S.
Oncogene. 2008 Sep 11;27(40):5348-53. Epub 2008 Jun 9.
PMID 18542058
Role of the TMPRSS2-ERG gene fusion in prostate cancer.
Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM.
Neoplasia. 2008a Feb;10(2):177-88.
PMID 18283340
The role of SPINK1 in ETS rearrangement-negative prostate cancers.
Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andren O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjartell AS, Chinnaiyan AM.
Cancer Cell. 2008b Jun;13(6):519-28.
PMID 18538735
Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.
Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M.
Cancer Res. 2008 Oct 15;68(20):8516-24.
PMID 18922926
Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, Zielenska M, Soares FA, Squire JA.
Mod Pathol. 2008 Dec;21(12):1451-60. Epub 2008 May 23.
PMID 18500259
HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.
Ai J, Wang Y, Dar JA, Liu J, Liu L, Nelson JB, Wang Z.
Mol Endocrinol. 2009 Dec;23(12):1963-72. Epub 2009 Oct 23.
PMID 19855091
TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma.
Albadine R, Latour M, Toubaji A, Haffner M, Isaacs WB, A Platz E, Meeker AK, Demarzo AM, Epstein JI, Netto GJ.
Mod Pathol. 2009 Nov;22(11):1415-22. Epub 2009 Sep 4.
PMID 19734849
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS.
Cancer Res. 2009 Apr 1;69(7):2912-8.
PMID 19339269
Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results.
Bonaccorsi L, Nesi G, Nuti F, Paglierani M, Krausz C, Masieri L, Serni S, Proietti-Pannunzi L, Fang Y, Jhanwar SC, Orlando C, Carini M, Forti G, Baldi E, Luzzatto L.
J Endocrinol Invest. 2009 Jul;32(7):590-6. Epub 2009 May 5.
PMID 19494719
ETS rearrangements and prostate cancer initiation.
Carver BS, Tran J, Chen Z, Carracedo-Perez A, Alimonti A, Nardella C, Gopalan A, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP.
Nature. 2009a Feb 12;457(7231):E1; discussion E2-3.
PMID 19212347
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.
Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP.
Nat Genet. 2009b May;41(5):619-24. Epub 2009 Apr 26.
PMID 19396168
TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA.
Cancer Biol Ther. 2009 Jan;8(2):125-30. Epub 2009 Feb 4.
PMID 19029822
Distinct genomic aberrations associated with ERG rearranged prostate cancer.
Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ, Pflueger D, Pina C, Hofer MD, Sboner A, Svensson MA, Rickman DS, Urban A, Snyder M, Meyerson M, Lee C, Gerstein MB, Kuefer R, Rubin MA.
Genes Chromosomes Cancer. 2009 Apr;48(4):366-80.
PMID 19156837
The role of the ETS factor erg in zebrafish vasculogenesis.
Ellett F, Kile BT, Lieschke GJ.
Mech Dev. 2009 Mar-Apr;126(3-4):220-9. Epub 2008 Nov 8.
PMID 19027849
Direct profiling of cancer biomarkers in tumor tissue using a multiplexed nanostructured microelectrode integrated circuit.
Fang Z, Soleymani L, Pampalakis G, Yoshimoto M, Squire JA, Sargent EH, Kelley SO.
ACS Nano. 2009 Oct 27;3(10):3207-13.
PMID 19736919
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.
Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, Eastham JA, Scardino PT, Scher HI, Tickoo SK, Reuter VE, Gerald WL.
Cancer Res. 2009 Feb 15;69(4):1400-6. Epub 2009 Feb 3.
PMID 19190343
Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion.
Guo CC, Zuo G, Cao D, Troncoso P, Czerniak BA.
Mod Pathol. 2009 Jul;22(7):866-71. Epub 2009 Apr 24.
PMID 19396154
Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair.
Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, Misri S, Zeng S, Pagan J, Jeffery J, Puc J, Kumar R, Feng Z, Powell SN, Bhat A, Yaguchi T, Wadhwa R, Kaul SC, Parsons R, Khanna KK, Pandita TK.
Cell Cycle. 2009 Jul 15;8(14):2198-210. Epub 2009 Jul 7.
PMID 19502790
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.
Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB.
Mod Pathol. 2009 Aug;22(8):1083-93. Epub 2009 May 1.
PMID 19407851
Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.
Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC, Trapman J.
Clin Cancer Res. 2009 Oct 15;15(20):6398-403. Epub 2009 Oct 13.
PMID 19825963
Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.
Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F, Paiss T, Vogel W, Rubin MA, Hoegel J.
Cancer Res. 2009 Jan 15;69(2):640-6.
PMID 19147579
Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer.
Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L, True LD, Roudier MP, Morrissey CM, Higano CS, Nelson PS, Vessella RL, Trask BJ.
Cancer Res. 2009 Oct 1;69(19):7793-802. Epub 2009 Sep 22.
PMID 19773449
High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer.
Ishkanian AS, Mallof CA, Ho J, Meng A, Albert M, Syed A, van der Kwast T, Milosevic M, Yoshimoto M, Squire JA, Lam WL, Bristow RG.
Prostate. 2009 Jul 1;69(10):1091-100.
PMID 19350549
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.
King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL.
Nat Genet. 2009 May;41(5):524-6. Epub 2009 Apr 26.
PMID 19396167
Dual requirement for the ETS transcription factors Fli-1 and Erg in hematopoietic stem cells and the megakaryocyte lineage.
Kruse EA, Loughran SJ, Baldwin TM, Josefsson EC, Ellis S, Watson DK, Nurden P, Metcalf D, Hilton DJ, Alexander WS, Kile BT.
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13814-9. Epub 2009 Jul 31.
PMID 19666492
Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer.
Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, Zhang J, Rose DW, Fu XD, Glass CK, Rosenfeld MG.
Cell. 2009 Dec 11;139(6):1069-83.
PMID 19962179
Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA.
Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M, Sanda MG.
Urology. 2009 Nov;74(5):1156-61. Epub 2009 Aug 3.
PMID 19647299
Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.
Luedeke M, Linnert CM, Hofer MD, Surowy HM, Rinckleb AE, Hoegel J, Kuefer R, Rubin MA, Vogel W, Maier C.
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3030-5. Epub 2009 Oct 27.
PMID 19861517
Induced chromosomal proximity and gene fusions in prostate cancer.
Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N, Chinnaiyan AM.
Science. 2009 Nov 27;326(5957):1230. Epub 2009 Oct 29.
PMID 19933109
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG.
Clin Cancer Res. 2009 Jul 15;15(14):4706-11. Epub 2009 Jul 7.
PMID 19584163
N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A, Kuefer R, Tewari AK, Demichelis F, Chee MS, Gerstein MB, Rubin MA.
Neoplasia. 2009 Aug;11(8):804-11.
PMID 19649210
Regulation of angiogenesis by ETS transcription factors.
Randi AM, Sperone A, Dryden NH, Birdsey GM.
Biochem Soc Trans. 2009 Dec;37(Pt 6):1248-53.(REVIEW)
PMID 19909256
SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.
Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F, Rubin MA.
Cancer Res. 2009 Apr 1;69(7):2734-8. Epub 2009 Mar 17.
PMID 19293179
TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.
Rostad K, Hellwinkel OJ, Haukaas SA, Halvorsen OJ, Oyan AM, Haese A, Budaus L, Albrecht H, Akslen LA, Schlomm T, Kalland KH.
APMIS. 2009 Aug;117(8):575-82.
PMID 19664128
Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner.
Schayek H, Haugk K, Sun S, True LD, Plymate SR, Werner H.
Clin Cancer Res. 2009 Mar 1;15(5):1558-65. Epub 2009 Feb 17.
PMID 19223505
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.
Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM.
Nature. 2009 Feb 12;457(7231):910-4.
PMID 19212411
Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN, Schroder FH.
BJU Int. 2009 Aug;104(4):438-48. Epub 2009 Jun 24. (REVIEW)
PMID 19558559
Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization.
Watson SK, Woolcock BW, Fee JN, Bainbridge TC, Webber D, Kinahan TJ, Lam WL, Vielkind JR.
Prostate. 2009 Jun 15;69(9):961-75.
PMID 19267368
Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts.
Barwick BG, Abramovitz M, Kodani M, Moreno CS, Nam R, Tang W, Bouzyk M, Seth A, Leyland-Jones B.
Br J Cancer. 2010 Feb 2;102(3):570-6. Epub 2010 Jan 12.
PMID 20068566
TMPRSS2-ERG gene fusion in transition zone prostate cancer.
Bismar TA, Trpkov K.
Mod Pathol. 2010 Jul;23(7):1040-1; author reply 1041-2.
PMID 20596054
Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naive, node-positive prostate cancer.
Boormans JL, Hermans KG, Made AC, van Leenders GJ, Wildhagen MF, Collette L, Schroder FH, Trapman J, Verhagen PC.
Eur Urol. 2010 May;57(5):830-5. Epub 2009 Aug 22.
PMID 19716227
Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.
Esgueva R, Perner S, J LaFargue C, Scheble V, Stephan C, Lein M, Fritzsche FR, Dietel M, Kristiansen G, Rubin MA.
Mod Pathol. 2010 Apr;23(4):539-46. Epub 2010 Jan 29.
PMID 20118910
ERG rearrangement is present in a subset of transition zone prostatic tumors.
Falzarano SM, Navas M, Simmerman K, Klein EA, Rubin MA, Zhou M, Magi-Galluzzi C.
Mod Pathol. 2010 Nov;23(11):1499-506. Epub 2010 Aug 6.
PMID 20693982
TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.
Fine SW, Gopalan A, Leversha MA, Al-Ahmadie HA, Tickoo SK, Zhou Q, Satagopan JM, Scardino PT, Gerald WL, Reuter VE.
Mod Pathol. 2010 Oct;23(10):1325-33. Epub 2010 Jun 18.
PMID 20562851
ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.
Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, Thangapazham R, Chen Y, McMaster G, Sreenath T, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA.
Prostate Cancer Prostatic Dis. 2010 Sep;13(3):228-37. Epub 2010 Jun 29.
PMID 20585344
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.
Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S.
Nat Genet. 2010 Aug;42(8):668-75. Epub 2010 Jul 4.
PMID 20601956
Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.
Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G.
Prostate Cancer Prostatic Dis. 2010 Dec;13(4):311-5. Epub 2010 Sep 7.
PMID 20820186
Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity.
Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y.
Prostate. 2010 May 15;70(7):745-54.
PMID 20058237
TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients.
Lee K, Chae JY, Kwak C, Ku JH, Moon KC.
Urology. 2010 Nov;76(5):1268.e7-13. Epub 2010 Aug 30.
PMID 20800881
Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer.
Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saramaki OR, Visakorpi T.
Clin Cancer Res. 2010 May 15;16(10):2845-51. Epub 2010 May 4.
PMID 20442300
TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african-american and japanese patients.
Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, Lafargue C, Esgueva R, Klein E, Rubin MA, Zhou M.
Prostate. 2010 Sep 28. [Epub ahead of print]
PMID 20878952
Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis.
Mao X, Yu Y, Boyd LK, Ren G, Lin D, Chaplin T, Kudahetti SC, Stankiewicz E, Xue L, Beltran L, Gupta M, Oliver RT, Lemoine NR, Berney DM, Young BD, Lu YJ.
Cancer Res. 2010 Jul 1;70(13):5207-12. Epub 2010 Jun 1.
PMID 20516122
ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.
Miyagi Y, Sasaki T, Fujinami K, Sano J, Senga Y, Miura T, Kameda Y, Sakuma Y, Nakamura Y, Harada M, Tsuchiya E.
Mod Pathol. 2010 Nov;23(11):1492-8. Epub 2010 Aug 6.
PMID 20693979
Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status.
Mwamukonda K, Chen Y, Ravindranath L, Furusato B, Hu Y, Sterbis J, Osborn D, Rosner I, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G.
Prostate Cancer Prostatic Dis. 2010 Mar;13(1):47-51. Epub 2009 Jul 14.
PMID 19597533
Antibody-based detection of ERG rearrangement-positive prostate cancer.
Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T, Srivastava A, Tewari AK, Sathyanarayana U, Nagy D, Pestano G, Kunju LP, Demichelis F, Chinnaiyan AM, Rubin MA.
Neoplasia. 2010 Jul;12(7):590-8.
PMID 20651988
ERG rearrangement metastasis patterns in locally advanced prostate cancer.
Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, Jarleborn AR, Hofer MD, Kuefer R, Demichelis F, Rickman DS, Rubin MA.
Urology. 2010 Apr;75(4):762-7.
PMID 20018353
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.
Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS.
Br J Cancer. 2010 Feb 16;102(4):678-84. Epub 2010 Jan 26.
PMID 20104229
Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.
Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, Ibrahim M, Elsamanoudi S, Brassell S, Furusato B, Stingle N, Sesterhenn IA, Petrovics G, Miick S, Rittenhouse H, Groskopf J, McLeod DG, Srivastava S.
Clin Cancer Res. 2010 Mar 1;16(5):1572-6. Epub 2010 Feb 16.
PMID 20160063
Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J, Fernandez-Serra A, Calatrava A, Garcia-Casado Z, Rubio L, Bonillo MA, Iborra I, Solsona E, Lopez-Guerrero JA.
J Urol. 2010 May;183(5):2054-61. Epub 2010 Mar 19.
PMID 20303538
ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.
Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl M, Kuefer R, Schilling D, Fend F, Kristiansen G, Meyerson M, Rubin MA, Bubendorf L, Perner S.
Mod Pathol. 2010 Aug;23(8):1061-7. Epub 2010 May 14.
PMID 20473283
Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation.
Schulz WA, Ingenwerth M, Djuidje CE, Hader C, Rahnenfuhrer J, Engers R.
BMC Cancer. 2010 Sep 22;10:505.
PMID 20860828
The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer.
Shan L, Ambroisine L, Clark J, Yanez-Munoz RJ, Fisher G, Kudahetti SC, Yang J, Kia S, Mao X, Fletcher A, Flohr P, Edwards S, Attard G, De-Bono J, Young BD, Foster CS, Reuter V, Moller H, Oliver TD, Berney DM, Scardino P, Cuzick J, Cooper CS, Lu YJ.
Prostate Cancer Prostatic Dis. 2010 Jun;13(2):117-25. Epub 2010 Feb 23.
PMID 20177423
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.
Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S.
Sci Transl Med. 2010 Mar 31;2(25):25ra23.
PMID 20424012
Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study.
Sun QP, Li LY, Chen Z, Pang J, Yang WJ, Zhou XF, Qiu JG, Su ZL, He D, Gao X.
J Mol Diagn. 2010 Sep;12(5):718-24. Epub 2010 Jul 8.
PMID 20616363
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.
Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, Chen YB, Esgueva R, Banerjee S, LaFargue CJ, Siddiqui J, Demichelis F, Moeller P, Bismar TA, Kuefer R, Fullen DR, Johnson TM, Greenson JK, Giordano TJ, Tan P, Tomlins SA, Varambally S, Rubin MA, Maher CA, Chinnaiyan AM.
Nat Med. 2010 Jul;16(7):793-8. Epub 2010 Jun 6.
PMID 20526349
Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization.
Zhang S, Pavlovitz B, Tull J, Wang Y, Deng FM, Fuller C.
Diagn Mol Pathol. 2010 Sep;19(3):151-6.
PMID 20736744
PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA, Yoshimoto M, Vollmer RT, Duan Q, Firszt M, Corcos J, Squire JA.
BJU Int. 2011 Feb;107(3):477-485. doi: 10.1111/j.1464-410X.2010.09470.x.
PMID 20590547
Written2010-12Julia L Williams, Maisa Yoshimoto, Alexander H Boag, Jeremy A Squire, Paul C Park
of Pathology, Molecular Medicine, Queen's University, Kingston, Ontario, Canada (JLW, MY, AHB, JAS); Kingston General Hospital, 76 Stuart Street, Douglas 4, Room 8-431, Kingston, Ontario, K7L 2V7 Canada (PCP)


This paper should be referenced as such :
Williams, JL ; Yoshimoto, M ; Boag, AH ; Squire, JA ; Park, PC
TMPRSS2:ETS gene fusions in prostate cancer
Atlas Genet Cytogenet Oncol Haematol. 2011;15(8):699-716.
Free journal version : [ pdf ]   [ DOI ]
On line version :